CMG Pharmaceutical Co Ltd

CMG Pharmaceutical Co Ltd has a market price of 1,379 KRW per share, with a market capitalization of 203,874,370,357 KRW. The company's price-to-book ratio is 1.01, and its price-to-tangible-book ratio is also 1.01, indicating that the market value is closely aligned with the book value of the company's tangible assets. The enterprise value to EBITDA ratio is negative at -31.15, reflecting the company's current operating losses. The enterprise value to revenue ratio is 2.62, suggesting that the company is trading at a moderate multiple relative to its revenue. The company's profitability metrics are weak, with a return on equity of -5% and a return on assets of -3.29%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The gross profit margin is 58.0%, but the operating margin is negative at -8.4%, and the net margin is also negative at -9.6%. These metrics suggest that the company is struggling to control its operating expenses and is not generating sufficient operating income to cover its costs. CMG Pharmaceutical Co Ltd's revenue is concentrated in a single geographic market, South Korea, with no disclosed international operations. The company does not report segment data, so it is unclear whether its product lines or therapeutic areas are contributing differently to its financial performance. The lack of diversification in both geography and product lines increases the company's exposure to local economic and regulatory risks. The company's growth trajectory is negative, with a net income of -10,077,182,180 KRW and an operating income of -8,857,838,210 KRW. The operating cash flow is also negative at -11,020,197,870 KRW, and the free cash flow is -40,008,258,720 KRW. These figures indicate that the company is not generating sufficient cash from operations to fund its capital expenditures or to service its debt. The capital expenditure for the period is -33,013,126,380 KRW, which is a significant outflow of cash. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The debt-to-equity ratio is 0.36, indicating that the company is not overly leveraged. However, the current ratio is 0.92, suggesting that the company may have difficulty meeting its short-term obligations. The key risk flag is that the company has negative net cash after subtracting total debt, which could limit its ability to invest in growth opportunities or to withstand financial shocks. There are no recent events or filings disclosed in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial performance and risk profile suggest that it is in a challenging position and may require strategic adjustments to improve its profitability and liquidity.